Criteria to qualify for study: | Drug used in study: |
---|---|
|
ALL 06 An Open-Label, Multi-Centre, Phase lb/ll study evaluating the safety and efficacy of Auto1, A CAR-T Cell treatment targeting CD19 in adult patients with relapsed of refractory B Cell Acute Lymphoblastic Leukemia. |
Criteria to qualify for study: | Drug used in study: |
---|---|
|
HR 62 A Phase ½ open label clinical trial of TC-100 T Cells in adults with relapsed or refractory Non Hodgkin Lymphoma (NHL) or Acute Lymphoblastic Leukemia |